Net Cash Provided by (Used in) Financing Activities of INTEGRATED BIOPHARMA INC from 30 Sep 2010 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
INTEGRATED BIOPHARMA INC quarterly and annual Net Cash Provided by (Used in) Financing Activities in USD history and change rate from 30 Sep 2010 to 30 Sep 2025.
  • INTEGRATED BIOPHARMA INC Net Cash Provided by (Used in) Financing Activities for the quarter ending 30 Sep 2025 was $11,000, a 57% decline year-over-year.
  • INTEGRATED BIOPHARMA INC annual Net Cash Provided by (Used in) Financing Activities for 2025 was $78,000.
  • INTEGRATED BIOPHARMA INC annual Net Cash Provided by (Used in) Financing Activities for 2024 was $29,000, a 79% increase from 2023.
  • INTEGRATED BIOPHARMA INC annual Net Cash Provided by (Used in) Financing Activities for 2023 was $136,000, a 96% increase from 2022.
Source SEC data
View on sec.gov
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Change (%)
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Change (%)

INTEGRATED BIOPHARMA INC Quarterly Net Cash Provided by (Used in) Financing Activities (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $11,000 -$4,000 -57% 01 Jul 2025 30 Sep 2025 10-Q 10 Nov 2025 2026 Q1
Q3 2024 $7,000 -$10,000 -333% 01 Jul 2024 30 Sep 2024 10-Q 10 Nov 2025 2026 Q1
Q3 2023 $3,000 +$108,000 01 Jul 2023 30 Sep 2023 10-Q 13 Nov 2024 2025 Q1
Q3 2022 $105,000 +$2,018,000 +95% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023 2024 Q1
Q3 2021 $2,123,000 -$129,000 -6.5% 01 Jul 2021 30 Sep 2021 10-Q 10 Nov 2022 2023 Q1
Q3 2020 $1,994,000 -$417,000 -26% 01 Jul 2020 30 Sep 2020 10-Q 10 Nov 2021 2021 Q1
Q3 2019 $1,577,000 -$1,147,000 -267% 01 Jul 2019 30 Sep 2019 10-Q 12 Nov 2020 2021 Q1
Q3 2018 $430,000 +$915,000 +68% 01 Jul 2018 30 Sep 2018 10-Q 13 Nov 2019 2020 Q1
Q3 2017 $1,345,000 -$1,609,000 -609% 01 Jul 2017 30 Sep 2017 10-Q 09 Nov 2018 2019 Q1
Q3 2016 $264,000 +$646,000 01 Jul 2016 30 Sep 2016 10-Q 09 Nov 2017 2018 Q1
Q3 2015 $382,000 -$888,000 -175% 01 Jul 2015 30 Sep 2015 10-Q 10 Nov 2016 2017 Q1
Q3 2014 $506,000 +$848,000 01 Jul 2014 30 Sep 2014 10-Q 05 Nov 2015 2016 Q1
Q3 2013 $342,000 -$529,000 -283% 01 Jul 2013 30 Sep 2013 10-Q 07 Nov 2014 2015 Q1
Q3 2012 $187,000 +$199,000 01 Jul 2012 30 Sep 2012 10-Q 14 Nov 2013 2014 Q1
Q3 2011 $12,000 -$41,000 -141% 01 Jul 2011 30 Sep 2011 10-Q 19 Nov 2012 2013 Q1
Q3 2010 $29,000 01 Jul 2010 30 Sep 2010 10-Q 21 Nov 2011 2012 Q1

INTEGRATED BIOPHARMA INC Annual Net Cash Provided by (Used in) Financing Activities (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $78,000 +$107,000 01 Jul 2024 30 Jun 2025 10-K 23 Sep 2025 2025 FY
2024 $29,000 +$107,000 +79% 01 Jul 2023 30 Jun 2024 10-K 23 Sep 2025 2025 FY
2023 $136,000 +$3,369,000 +96% 01 Jul 2022 30 Jun 2023 10-K 20 Sep 2024 2024 FY
2022 $3,505,000 -$462,000 -15% 01 Jul 2021 30 Jun 2022 10-K 15 Sep 2023 2023 FY
2021 $3,043,000 -$1,741,000 -134% 01 Jul 2020 30 Jun 2021 10-K 13 Sep 2022 2022 FY
2020 $1,302,000 -$1,643,000 -482% 01 Jul 2019 30 Jun 2020 10-K 02 Sep 2021 2021 FY
2019 $341,000 +$1,171,000 01 Jul 2018 30 Jun 2019 10-K 23 Sep 2020 2020 FY
2018 $830,000 -$497,000 -149% 01 Jul 2017 30 Jun 2018 10-K 29 Aug 2019 2019 FY
2017 $333,000 -$1,358,000 -132% 01 Jul 2016 30 Jun 2017 10-K 12 Sep 2018 2018 FY
2016 $1,025,000 +$1,136,000 01 Jul 2015 30 Jun 2016 10-K 02 Sep 2016 2016 FY
2015 $111,000 +$1,188,000 +91% 01 Jul 2014 30 Jun 2015 10-K 02 Sep 2016 2016 FY
2014 $1,299,000 -$2,658,000 -196% 01 Jul 2013 30 Jun 2014 10-K 04 Sep 2015 2015 FY
2013 $1,359,000 +$1,025,000 +307% 01 Jul 2012 30 Jun 2013 10-K 08 Sep 2014 2014 FY
2012 $334,000 +$379,000 01 Jul 2011 30 Jun 2012 10-K 30 Sep 2013 2013 FY
2011 $45,000 01 Jul 2010 30 Jun 2011 10-K 15 Oct 2012 2012 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.